By Zac Ezzone for the Triangle Business Journal
The Triangle has gained another public company through a headquarters relocation.
Simulations Plus (Nasdaq: SLP) has moved its headquarters from southern California to Research Triangle Park. The company provides software and consulting services in the biopharmaceutical sector.
The move comes as Simulations also fully exits four office locations in California, New York, Pennsylvania and Raleigh. The office closures and headquarters relocations are “in support of the company’s remote work culture and plan to reduce excess office space to achieve its carbon footprint reduction targets,” according to the company’s latest financial filing.
The company declined to comment on the relocation beyond its latest financial filing. Simulations, in the filing, lists 800 Park Offices Drive, Ste. 401 in RTP as the address of its executive offices. The company also maintains an office in Paris.
Simulations reported revenue for the six-month period that ended in February of $41.36 million, up from $32.81 million from the same six-month period last year. The company expects total revenue in fiscal year 2025 between $90 million and $93 million.
The company has a market cap of $500 million. Its stock was trading above $25 Wednesday as markets rallied on news that President Donald Trump is pausing most tariffs for 90-days.
As of August 2024, Simulations had 243 full-time employees.
This is the second public company to make a similar move in recent months. The pharmaceutical company Heron Therapeutics (Nasdaq: HRTX) late last year moved its corporate headquarters from California to Cary.
Simulations’ relocation follows the company last year acquiring Pro-ficiency, a Raleigh-based firm that provides training and compliance solutions to clinical trial investigators, for $100 million. Pro-ficiency was backed by local investor QHP Capital.
With this acquisition, Simulations “extended its reach across the drug development value chain from the initial protocol stage through all phases of clinical research and development (“R&D”) to product commercialization,” according to the company’s latest financial filing.
“Simulations Plus now has a one-of-a-kind platform to serve its clients at every step in the drug development process,” the company said in the filing.
The preceding article originally appeared on April 9, 2025 at the Triangle Business Journal’s website and is made available here for educational purposes only. This constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 106A-117 of the U.S. Copyright Law. Any views or opinions expressed here are those of the authors and do not necessarily reflect the official policy or position of the Carolina Leadership Coalition.
